FY2025 · period end Dec '25 · from the 10-K filed Feb 20, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.68B | $2.55B | $9.96B | $9.79B |
| Gross Profit | $1.44B | $2.22B | $2.13B | $1.83B | $1.51B |
| Operating Income | $0.03B | negative: -$0.22B | $0.13B | $0.14B | $0.37B |
| Net Income | negative: -$1.10B | negative: -$0.36B | negative: -$0.04B | $0.02B | $0.22B |
| EPS (Diluted) | negative: -$14.31 | negative: -$4.73 | negative: -$0.53 | $0.29 | $2.94 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $2.45B | $4.66B | $5.09B | $5.39B | $3.54B |
| Total Liabilities | $2.91B | $4.07B | $4.17B | $4.44B | $2.60B |
| Stockholders' Equity | negative: -$0.46B | $0.59B | $0.95B | $0.97B | $0.94B |
| Cash & Equivalents | $0.28B | $0.03B | $0.24B | $0.07B | $0.06B |
| Total Debt | $1.80B | $1.80B | $1.89B | $2.48B | $0.95B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | — | $0.16B | $0.74B | $0.33B | $0.12B |
| Capital Expenditures | $0.19B | $0.17B | $0.17B | $0.16B | $0.04B |
| Free Cash Flow | — | negative: -$0.01B | $0.57B | $0.17B | $0.08B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 52.1% | 82.8% | 83.3% | 18.3% | 15.5% |
| Operating Margin | 1.0% | negative: -8.1% | 5.2% | 1.4% | 3.8% |
| Net Margin | negative: -39.8% | negative: -13.5% | negative: -1.6% | 0.2% | 2.3% |
| Return on Equity | 238.8% | negative: -61.9% | negative: -4.4% | 2.3% | 23.6% |
| Return on Assets | negative: -44.9% | negative: -7.8% | negative: -0.8% | 0.4% | 6.3% |
| Debt / Equity | negative: -3.90× | 3.07× | 2.00× | 2.57× | 1.01× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001104659-26-097517 | Aug 17, 2026 | Aug 17, 2026 | Aug 17, 2026 10:42 UTC | EDGAR |
| 8-K | 0001104659-26-093381 | Aug 9, 2026 | Aug 10, 2026 | Aug 10, 2026 20:15 UTC | EDGAR |
| 10-Q | 0001104659-26-093177 | Jun 30, 2026 | Aug 10, 2026 | Aug 10, 2026 15:15 UTC | EDGAR |
| 8-K | 0001104659-26-092999 | Aug 10, 2026 | Aug 10, 2026 | Aug 10, 2026 10:50 UTC | EDGAR |
| 8-K | 0001104659-26-092973 | Aug 10, 2026 | Aug 10, 2026 | Aug 10, 2026 10:36 UTC | EDGAR |
| 8-K | 0001193125-26-282808 | Jun 23, 2026 | Jun 25, 2026 | Jun 25, 2026 20:15 UTC | EDGAR |
| 8-K | 0001193125-26-271115 | Jun 9, 2026 | Jun 15, 2026 | Jun 15, 2026 20:15 UTC | EDGAR |
| 8-K | 0001193125-26-236869 | May 22, 2026 | May 22, 2026 | May 22, 2026 20:08 UTC | EDGAR |
Direct links to SEC EDGAR. ACH has additional filings available on the SEC site.
6 numbers ACCENDRA HEALTH INC/VA/ later changed — same XBRL tag, both filings linked.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2025
Major restatementwas-$35.1M
Revised up in a 10-Q.
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2023
Major restatementwas$10.3B
Revised down in a 10-K. Any P/S built on the original was 304.8% too low.
Revenue from Contract with Customer, Excluding Assessed Tax·Q2 2024
Major restatementwas$2.7B
Revised down in a 10-Q. Any P/S built on the original was 304.5% too low.
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2024
Major restatementwas$10.7B
Revised down in a 10-K. Any P/S built on the original was 299.3% too low.
Revenue from Contract with Customer, Excluding Assessed Tax·Q3 2024
Major restatementwas$2.7B
Revised down in a 10-Q. Any P/S built on the original was 296.2% too low.
Revenue from Contract with Customer, Excluding Assessed Tax·Q1 2025
Major restatementwas$2.6B
Revised down in a 10-Q. Any P/S built on the original was 290.6% too low.
ACH is not the only one.
See every restatement we've found across the market — or get an alert the next time ACH revises a number.
Restatements are detected by comparing every vintage of a fact across all of ACCENDRA HEALTH INC/VA/'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ACH's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling ACCENDRA HEALTH INC/VA/ — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ACH yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ACH and publish the result to your public profile.
Ask about ACCENDRA HEALTH INC/VA/
Continue in Workspace — cited answers on ACH, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs